TCELS join hand Malaysia plans to sign an MOU on the development of vaccines- medical devices

Food and Healthcare Press Releases Thursday November 28, 2013 10:40
Bangkok--28 Nov--TCELS
TCELS forges an alliance with Malaysia and plans to sign an MOU on the development of vaccines medicine and production of medical devices.

Malaysia’s bioeconomy is regarded to be the propelling force of the government’s business growth agenda and is predicted to boost the country’s wealth in 2020. Thailand too is moving forward to become Asia Pacific’s centre of excellence for life sciences.

Dr.Nares Damrongchai, CEO of Thailand Centre of Excellence for Life Sciences (TCELS) under the Ministry of Science and Technology said that TCELS’s representatives led by Somchai Tiamboonprasert, the Ministry of Science and Technology’s deputy permanent secretary and also TCELS’ board member, attended BioMalaysia 2013 organized at Johor Bahru to build up a network of life science contacts among Asia-Pacific countries.

According to Dr. Nares, BioMalaysia 2013 is a business affiliation of the government and private sectors as well as biotechnology entrepreneurs to form a connection among that related parties and to promote bioeconomy in Asia Pacific region. This year, representatives from over 10 countries participated in the programme and TCELS represented Thailand. In the Exhibition, TCELS representatives came up with life sciences innovation including rubber latex extraction and cell and gene therapy projects that grabbed the attention of Malaysian entrepreneurs and investors who showed interest in these projects.

Through this participation is BioMalaysia 2013, has forged a relationship with BiotechCorp, a Malaysian company that is formed by business collaboration between Malaysia’s Ministry of Finance, Ministry of Science, Technology and Innovation and Federal Lands Commission. This new alliance is making steady progress. A Memorandum of Understanding (MOU) is being prepared on the development of vaccines, production of medical devices and their testing before being used in clinics as well as human resource development.

In addition, an idea of seeking business partners to bring a business venture among Thai and Malaysian investors was also mentioned in the meeting. It is recommended that Thailand and Malaysia would run the programme on alternate year. BiotechCorp advised about forming an alliance to work on biotechnology and biofuel and working hand in hand with various sectors including Ministry of Science and Technology, National Science and Technology Development Agency (NSTDA) and Thailand Institute of Scientific and Technological Research (TISTR).

Dr. Nares pointed out that Malaysia has a firm economic base in the field of biotechnology as the country has a clear policy and well – defined goals to boost the bio- economy and develop strategies to support the industry. Malaysian government aims to achieve the goal of producing 3.6 billion ringgits of Gross Domestic Product (GDP) and generating 10.6 billion ringgits worth of investment and creating about 16,300 job opportunities by 2020. Organization for Economic Co-operation and Development (OECD) forecasts that Malaysia’s bio- economy will make up 2.7% of the world’s total GDP in 2030.

While, Thailand’s TCELS has a goal to be a centre of excellence of life sciences in the Asia Pacific region. To achieve this goal, the country is moving ahead with their plans to develop high quality academics, improve medical services and give support to medical devices industry. The development of medical robotics and cell therapy development is also TCELS another important strategy to achieve this goal.


Latest Press Release

Medical Device Manufacturer Advant Medical Celebrates Its 25th Anniversary

Advant is a successful medical device manufacturer with corporate offices located in Galway, Ireland. For a quarter of a century, Advant has seen significant growth and development expanding into two locations in Ireland, Mexico and Costa Rica. With over...

Michel Orsinger Assumes Role as Chairman of Limacorporate#s Advisory Board

LimaCorporate is pleased to announce that Michel Orsinger, Board Member of LimaCorporate's Advisory Board, will assume the role of Chairman of the Board. Michel joined the Advisory Board mid-2017 following a long and successful global career in...

Merck and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxorubicin (PLD), a type of chemotherapy, compared with PLD did not meet the...

APEC#s Rare Disease Action Plan Sets Precedent to Integrate Rare Disease Care by 2025

- Asia-Pacific Economic Cooperation (APEC) Life Sciences Innovation Forum (LSIF) Rare Disease Network comprises Rare Disease International, Queensland University of Technology and Shire (representing as industry co-chair). - Aims to define, diagnose and...

Grunenthal Acquires Averitas Pharma and Establishes Commercial Footprint in the US

Grunenthal announced today that it has acquired the US-based pharmaceutical company Averitas Pharma, thereby extending its commercial footprint to the United States. Averitas Pharma will be commercialising the pain patch Qutenza(R) (8 % capsaicin) for...

Related Topics